An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients

被引:3
作者
Capdepont, S
Aurillac-Lavignolle, V
Faure, M
Dupon, M
Morlat, P
Ragnaud, JM
Chêne, G
Fleury, H
Masquelier, B
机构
[1] CHU Bordeaux, Dept Virol & Immunol Biol, F-33076 Bordeaux, France
[2] Univ Victor Segalen, EA 2968, Bordeaux, France
[3] Univ Victor Segalen, INSERM, U593, Bordeaux, France
[4] CHU Bordeaux, Dept Malad Infect, Bordeaux, France
关键词
HIV drug resistance; didanosine; algorithm; nucleoside RT inhibitors;
D O I
10.1016/j.jcv.2006.01.008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objective: To assess the genotypic determinants of the virological response (VR) to didanosine (ddl) in nucleoside reverse transcriptase inhibitors (NRTI)-experienced patients. Methods: Human immunodeficiency virus type 1 (HIV-1) genotype was determined at baseline in 74 ddI-naive-patients with baseline viral load >500 copies/ml and receiving ddl as part of a new regimen. VR was defined as a plasma HIV-1 RNA <50 copies/ml after three months on ddl. NRTI resistance mutations associated with higher or lower frequencies of VR with a p-value < 0.25 were retained in different sets of mutations, where the mutations associated with a worse VR were added, whereas the mutations associated with a better VR were substracted. The most significant mutation scores were then studied in a multivariate analysis. Results: Changes at three codons (M41L L210W, T215Y/F/D/C/E) were associated with a worse VR and three mutations (K70R, M184V, K219Q) with a better VR. The strongest association with the VR was obtained with the score M41L + L210W + T215Y/F/D/C/E - K70R - K219Q. The score was independently associated with the VR in the multivariate analysis. Conclusion: Taking into account the mutations associated with a better VR may improve genotypic resistance algorithms. Our results are of interest for the management of antiretroviral therapy in NRTI -experienced patients. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 30 条
[1]   The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1 [J].
Boyer, PL ;
Sarafianos, SG ;
Arnold, E ;
Hughes, SH .
JOURNAL OF VIROLOGY, 2002, 76 (07) :3248-3256
[2]  
Brun-Vézinet F, 2004, ANTIVIR THER, V9, P465
[3]  
Brun-Vézinet F, 2003, AIDS, V17, P1795, DOI [10.1097/00002030-200308150-00008, 10.1097/01.aids.0000072669.21517.db]
[4]  
COSTAGLIOLA D, 2001, 8 C RETR OPP INF
[5]   Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity [J].
Diallo, K ;
Marchand, B ;
Wei, X ;
Cellai, L ;
Götte, M ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 2003, 77 (16) :8621-8632
[6]   INVITRO SELECTION OF VARIANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESISTANT TO 3'-AZIDO-3'-DEOXYTHYMIDINE AND 2',3'-DIDEOXYINOSINE [J].
GAO, Q ;
GU, ZX ;
PARNIAK, MA ;
LI, XG ;
WAINBERG, MA .
JOURNAL OF VIROLOGY, 1992, 66 (01) :12-19
[7]   THE SAME MUTATION THAT ENCODES LOW-LEVEL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE CONFERS HIGH-LEVEL RESISTANCE TO THE (-) ENANTIOMER OF 2',3'-DIDEOXY-3'-THIACYTIDINE [J].
GAO, Q ;
GU, ZX ;
PARNIAK, MA ;
CAMERON, J ;
CAMMACK, N ;
BOUCHER, C ;
WAINBERG, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1390-1392
[8]   Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].
Hirsch, MS ;
Brun-Vézinet, F ;
Clotet, B ;
Conway, B ;
Kuritzkes, DR ;
D'Aquila, RT ;
Demeter, LM ;
Hammer, SM ;
Johnson, VA ;
Loveday, C ;
Mellors, JW ;
Jacobsen, DM ;
Richman, DD .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128
[9]   Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy [J].
Iversen, AKN ;
Shafer, RW ;
Wehrly, K ;
Winters, MA ;
Mullins, JI ;
Chesebro, B ;
Merigan, TC .
JOURNAL OF VIROLOGY, 1996, 70 (02) :1086-1090
[10]  
Izopet J, 1999, J MED VIROL, V59, P507, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt